<DOC>
	<DOCNO>NCT01141322</DOCNO>
	<brief_summary>Cholestatic drug-induced liver injury ( DILI ) severe form DILI grave outcome . Drug-metabolizing enzyme play important role metabolism drug . The genetic polymorphism drug-metabolizing enzyme may influence activity expression enzymes thereby affect susceptibility severity DILI . UDP-glucuronosyltransferase ( UGT ) important phase 2 detoxification enzyme , related congenital hyperbilirubinemia . Recently , genetic polymorphism UGT1A1 report associated jaundice induce drug , UGT1A7 show related susceptibility hepatocellular carcinoma cancer . Ursodeoxycholic acid ( UDCA ) hydrophilic bile acid increasingly use treatment various cholestatic disorder . The aim study ( 1 ) ass association genetic polymorphism UGT1A1 1A7 , susceptibility severity drug-induced liver injury ( DILI ) , emphasis cholestatic DILI ; ( 2 ) evaluate treatment effect UDCA DILI , special reference cholestatic hepatotoxicity .</brief_summary>
	<brief_title>Cholestatic Drug-induced Liver Injury</brief_title>
	<detailed_description>Cholestatic drug-induced liver injury ( DILI ) severe form DILI grave outcome . Drug-metabolizing enzyme play important role metabolism drug . The genetic polymorphism drug-metabolizing enzyme may influence activity expression enzymes thereby affect susceptibility severity DILI . UDP-glucuronosyltransferase ( UGT ) important phase 2 detoxification enzyme , related congenital hyperbilirubinemia . Recently , genetic polymorphism UGT1A1 report associated jaundice induce drug , UGT1A7 show related susceptibility hepatocellular carcinoma cancer . Ursodeoxycholic acid ( UDCA ) hydrophilic bile acid increasingly use treatment various cholestatic disorder . The aim study ( 1 ) ass association genetic polymorphism UGT1A1 1A7 , susceptibility severity drug-induced liver injury ( DILI ) , emphasis cholestatic DILI ; ( 2 ) evaluate treatment effect UDCA DILI , special reference cholestatic hepatotoxicity . Owing limited number DILI patient , 3 year need study . Each year , total 60 patient DILI 60 age- sex-matched control enrol study . Their genetic polymorphism UGT1A1 UGT1A7 assess use real time PCR , PCR RFLP . The DILI patient randomize UDCA Treatment group Control group . UDCA 13-15 mg/kg/day 3 divided dos administer patient Treatment group . The frequency genotypes UGT1A1 1A7 compare DILI case control , survival case non-survival case , cholestatic non-cholestatic case . Chi-square test , without Yates ' correction , use compare categorical parameter . A paired test perform compare continuous parameter . Odds ratio ( OR ) confidence interval ( CI ) calculate use logistic regression analysis . The multivariate logistic regression analysis apply check OR , adjust possible risk factor . Survival rate estimate survival curve base Kaplan-Meier method compare log-rank test UDCA Treatment group Control group . We believe pharmacogenetic study may help u realize pathogenesis cholestatic DILI , clinical trial elucidate therapeutic value UDCA DILI , especially cholestatic hepatotoxicity .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Drug-Induced Liver Injury</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>Druginduced liver injury , meet DILIN criterion . Other systemic disease may cause elevation liver enzyme : viral hepatitis , alcoholic liver disease , autoimmune hepatitis , primary biliary cirrhosis , Wilson 's disease , hemochromatosis , congestive heart failure , hypoxia , sepsis .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>drug-induced liver injury</keyword>
	<keyword>hepatitis , toxic</keyword>
	<keyword>ursodeoxycholic acid</keyword>
</DOC>